Synairgen plc

LSE SNG.L

Synairgen plc Market Capitalization on January 14, 2025: USD 7.53 M

Synairgen plc Market Capitalization is USD 7.53 M on January 14, 2025, a -52.75% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Synairgen plc 52-week high Market Capitalization is USD 19.59 M on May 21, 2024, which is 160.31% above the current Market Capitalization.
Synairgen plc 52-week low Market Capitalization is USD 6.58 M on January 08, 2025, which is -12.56% below the current Market Capitalization.
Synairgen plc average Market Capitalization for the last 52 weeks is USD 12.88 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

LSE: SNG.L

Synairgen plc

CEO	Mr. Richard Marsden
IPO Date	Oct. 26, 2004
Location	United Kingdom
Headquarters	Mailpoint 810
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.

Key trends

Past 5 years